March 2, 2018 10:24 AM EST

EpimAb nabs Bin Peng from NIBR; Jeffrey Chodakewitz exits Vertex; Christiana Stamoulis is president at Unum

Amber Tong

→ Christiana Stamoulis is getting busier at Unum Therapeutics as she adds the role of president to her CFO and head of corporate development …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EpimAb nabs Bin Peng from NIBR; Jeffrey Chodakewitz exits Vertex; Christiana Stamoulis is president at Unum

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

EpimAb nabs Bin Peng from NI­BR; Jef­frey Chodake­witz ex­its Ver­tex; Chris­tiana Sta­moulis is pres­i­dent at Unum

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

EpimAb nabs Bin Peng from NIBR; Jeffrey Chodakewitz exits Vertex; Christiana Stamoulis is president at Unum

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial